
CTSH Stock Forecast & Price Target
CTSH Analyst Ratings
Bulls say
Cognizant Tech Solns is positioned favorably because its strongest vertical, Financial Services, is still delivering double-digit growth through AI-driven modernization, large-deal execution, and wallet-share gains, while Health Sciences remains stable and CMT headwinds are easing. Despite the suspension of PERM filings in September and related cost pressure, the risk appears largely reflected in the share price, and management has multiple margin levers, including fixed-price contracts that now represent roughly half of revenue, workforce optimization, and Project LEAP. With $84 million incurred in Q2 on LEAP, the remaining $230–$320 million program costs spread through 2026 and benefits expected in FY27, the company’s improving operating margin path and strong free-cash-flow deployment support a constructive long-term outlook.
Bears say
Cognizant Tech Solns is facing a deteriorating fundamental backdrop as the suspension of the PERM program and broader scrutiny of visa usage threaten a core labor-arbitrage model that has long supported margins. With management already operating in a challenging regulatory environment aimed at curbing H1-B availability, the company may need to rely more heavily on higher-cost US talent while still expanding offshore hiring in India and other lower-cost regions. Its earnings power is also exposed to weak global economic growth, wage inflation, and foreign exchange risk, all of which can pressure revenue growth, profitability, and conversion of its large deal pipeline into profitable revenues.
This aggregate rating is based on analysts' research of Cognizant Technology Solutions and is not a guaranteed prediction by Public.com or investment advice.
CTSH Analyst Forecast & Price Prediction
Start investing in CTSH
Order type
Buy in
Order amount
Est. shares
0 shares